Bioventus, Inc. (BVS)
NASDAQ:BVS
Want to see BVS full AI Analyst Report?
Total Valuation
Bioventus has a market cap or net worth of $718.40M. The enterprise value is $826.99M.
Market Cap$718.40M
Enterprise Value$826.99M
Share Statistics
Bioventus has 67,748,050 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding67,748,050
Owned by Insiders32.13%
Owned by Institutions48.92%
Financial Efficiency
Bioventus’s return on equity (ROE) is 0.12 and return on invested capital (ROIC) is 10.79%.
Return on Equity (ROE)0.12
Return on Assets (ROA)0.03
Return on Invested Capital (ROIC)10.79%
Return on Capital Employed (ROCE)0.11
Revenue Per Employee610.85K
Profits Per Employee0.00
Employee Count930
Asset Turnover0.83
Inventory Turnover2.26
Valuation Ratios
The current PE Ratio of Bioventus is 20.6. Bioventus’s PEG ratio is -0.13.
PE Ratio20.6
PS Ratio0.87
PB Ratio2.69
Price to Fair Value2.69
Price to FCF6.94
Price to Operating Cash Flow5.70
PEG Ratio-0.13
Income Statement
In the last 12 months, Bioventus had revenue of 568.09M and earned 22.73M in profits. Earnings per share was 0.34.
Revenue568.09M
Gross Profit382.43M
Operating Income58.55M
Pretax Income25.71M
Net Income22.73M
EBITDA99.21M
Earnings Per Share (EPS)0.34
Cash Flow
In the last 12 months, operating cash flow was 102.94M and capital expenditures -2.31M, giving a free cash flow of 100.63M billion.
Operating Cash Flow102.94M
Free Cash Flow100.63M
Free Cash Flow per Share1.49
Dividends & Yields
Bioventus pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.78
52-Week Price Change37.32%
50-Day Moving Average9.63
200-Day Moving Average8.17
Relative Strength Index (RSI)43.18
Average Volume (3m)662.69K
Important Dates
Bioventus upcoming earnings date is Aug 11, 2026, After Close (Confirmed).
Last Earnings DateMay 6, 2026
Next Earnings DateAug 11, 2026
Ex-Dividend Date―
Financial Position
Bioventus as a current ratio of 1.70, with Debt / Equity ratio of 144.03%
Current Ratio1.70
Quick Ratio1.19
Debt to Market Cap0.60
Net Debt to EBITDA2.62
Interest Coverage Ratio2.21
Taxes
In the past 12 months, Bioventus has paid -1.56M in taxes.
Income Tax-1.56M
Effective Tax Rate-0.06
Enterprise Valuation
Bioventus EV to EBITDA ratio is 7.62, with an EV/FCF ratio of 10.58.
EV to Sales1.33
EV to EBITDA7.62
EV to Free Cash Flow10.58
EV to Operating Cash Flow10.22
Balance Sheet
Bioventus has $35.85M in cash and marketable securities with $272.08M in debt, giving a net cash position of -$236.23M billion.
Cash & Marketable Securities$35.85M
Total Debt$272.08M
Net Cash-$236.23M
Net Cash Per Share-$3.49
Tangible Book Value Per Share-$2.21
Margins
Gross margin is 67.78%, with operating margin of 10.31%, and net profit margin of 4.00%.
Gross Margin67.78%
Operating Margin10.31%
Pretax Margin4.53%
Net Profit Margin4.00%
EBITDA Margin17.46%
EBIT Margin9.19%
Analyst Forecast
The average price target for Bioventus is $14.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$14.33
Price Target Upside36.25% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast1.52%
EPS Growth Forecast―